Arkolith/Insider Trading/QNRX/Form 4

Dunn Gordon

Chief Financial OfficerQuoin Pharmaceuticals, Ltd. (QNRX) · full profile →Form 4 · filed Sep 11, 2024
Net Buying
Open-Market Buys
$23K
Open-Market Sells
$0
Net Open-Market Flow
$23K
Transactions
5
5 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 10, 2024Buy(P)10K$0.91$9K19K
Sep 10, 2024Buy(P)10K$0.71$7K29K
Sep 9, 2024Buy(P)4K$0.80$3K9K
Sep 9, 2024Buy(P)4K$0.78$3K5K
Sep 9, 2024Buy(P)856$0.80$685856

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-098940) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML